Transparency Market Research
COVID-19 Diagnostics Market Revenue to Cross USD 45.8 billion by 2031, Registering a Negative 7.9% CAGR Says, Transparency Market Research
September 13, 2023 06:20 ET | Transparency Market Research
Wilmington, Delaware, United States, Sept. 13, 2023 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. - The COVID-19 diagnostics market was estimated to have acquired US$ 79.8 billion in 2021....
AIM ImmunoTech to Present at the H.C. Wainwright 25th Annual Global Investment Conference
September 05, 2023 09:05 ET | AIM ImmunoTech Inc.
OCALA, Fla., Sept. 05, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that Thomas K. Equels, Chief Executive Officer of AIM, will present...
InflaRx on large white.jpg
InflaRx’s Marketing Authorization Application (MAA) for Vilobelimab for Treatment of Critically Ill COVID-19 Patients under Review by European Medicines Agency (EMA)
August 30, 2023 07:30 ET | InflaRx N.V.
MAA for vilobelimab was submitted in JulyMAA has been validated by EMA and is now under reviewRegulatory submission based on pivotal data from PANAMO Phase III trialCompany announces attendance at...
DriveThru Urgent Care flagship location now open in Atlanta
August 24, 2023 12:00 ET | Viral Solutions LLC
ATLANTA, Aug. 24, 2023 (GLOBE NEWSWIRE) -- DriveThru Urgent Care — by Viral Solutions — is now seeing patients at its flagship location on Howell Mill Road in Atlanta. The practice treats patients...
July 30, 2021 - ROSEN LOGO.jpg
ROSEN, RESPECTED INVESTOR COUNSEL, Encourages Danaher Corporation Investors With Losses to Secure Counsel Before Important Deadline in Securities Class Action – DHR
August 20, 2023 13:52 ET | The Rosen Law Firm PA
NEW YORK, Aug. 20, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Danaher Corporation (NYSE: DHR) between April 21, 2022 and...
AIM ImmunoTech Reports Second Quarter Financial Results and Provides Clinical Pipeline Update
August 15, 2023 06:45 ET | AIM ImmunoTech Inc.
– Continued operational execution across pipeline towards multiple clinical and regulatory value-driving milestones expected in the second half of 2023 – Company to host conference call and...
InflaRx on large white.jpg
InflaRx Reports Second Quarter 2023 Financial Results & Operating Update
August 10, 2023 07:30 ET | InflaRx N.V.
• Quarter highlighted by the Emergency Use Authorization (EUA) and commercial launch of Gohibic (vilobelimab) in the United States • Oral C5aR inhibitor INF904 progressing in...
AIM ImmunoTech to Discuss Second Quarter 2023 Financial Results on August 15, 2023, and Host Conference Call and Webcast
August 09, 2023 09:05 ET | AIM ImmunoTech Inc.
OCALA, Fla., Aug. 09, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) announced today that management will host a conference call and webcast to discuss...
AIM ImmunoTech Announces Completion of Enrollment in Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions
August 08, 2023 08:05 ET | AIM ImmunoTech Inc.
OCALA, Fla., Aug. 08, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM”) today announced the completion of enrollment in the company’s Phase 2 study evaluating Ampligen® as a...
BrainHQ selected for NIH-funded Study for Long Covid Cognitive Issues
August 02, 2023 08:00 ET | Posit Science
SAN FRANCISCO, Aug. 02, 2023 (GLOBE NEWSWIRE) -- As announced by the US National Institutes of Health (NIH), BrainHQ is being incorporated into phase 2 clinical trials addressing persistent...